Yasara Manori Samarakoon1, Nalika Sepali Gunawardena2, Aloka Pathirana3, Manuja N Perera4, Sumudu Avanthi Hewage1. 1. National Cancer Control Programme, Ministry of Health, Nutrition and Indigenous Medicine, Colombo, Sri Lanka. 2. Department of Community Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. 3. Department of Surgery, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka. 4. Department of Public Health, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.
Abstract
BACKGROUND: Globally, colorectal cancer (CRC) is ranked as the third most common cancer in men and the second in women. Use of a simple, validated risk prediction tool will offer a low-cost mechanism to identify the high-risk individuals for CRC. This will increase efficient use of limited resources and early identification of patients. The aim of our study was to develop and validate a risk prediction model for developing CRC for Sri Lankan adults. METHODS: The risk predictors were based on the risk factors identified through a logistic regression model along with expert opinion. A case control design utilizing 65 CRC new cases and 65 hospital controls aged 30 years or more was used to assess the criterion validity and reliability of the model. The information was obtained using an interviewer administered questionnaire based on the risk prediction model. RESULTS: The developed model consisted of eight predictors with an area under the curve (AUC) of 0.849 (95% CI: 0.8 to 0.9, P<0.001). It has a sensitivity of 76.9%, specificity of 83.1%, positive predictive value (PPV) of 82.0%, negative predictive value (NPV) of 79.3%. Positive and negative likelihood ratios are 4.6 and 0.3. Test re-test reliability revealed a Kappa coefficient of 0.88. CONCLUSIONS: The model developed to predict the risk of CRC among adults aged 30 years and above was proven to be valid and reliable and it is an effective tool to be used as the first step to identify the high-risk population who should be referred for colonoscopy examination.
BACKGROUND: Globally, colorectal cancer (CRC) is ranked as the third most common cancer in men and the second in women. Use of a simple, validated risk prediction tool will offer a low-cost mechanism to identify the high-risk individuals for CRC. This will increase efficient use of limited resources and early identification of patients. The aim of our study was to develop and validate a risk prediction model for developing CRC for Sri Lankan adults. METHODS: The risk predictors were based on the risk factors identified through a logistic regression model along with expert opinion. A case control design utilizing 65 CRC new cases and 65 hospital controls aged 30 years or more was used to assess the criterion validity and reliability of the model. The information was obtained using an interviewer administered questionnaire based on the risk prediction model. RESULTS: The developed model consisted of eight predictors with an area under the curve (AUC) of 0.849 (95% CI: 0.8 to 0.9, P<0.001). It has a sensitivity of 76.9%, specificity of 83.1%, positive predictive value (PPV) of 82.0%, negative predictive value (NPV) of 79.3%. Positive and negative likelihood ratios are 4.6 and 0.3. Test re-test reliability revealed a Kappa coefficient of 0.88. CONCLUSIONS: The model developed to predict the risk of CRC among adults aged 30 years and above was proven to be valid and reliable and it is an effective tool to be used as the first step to identify the high-risk population who should be referred for colonoscopy examination.
Entities:
Keywords:
Colorectal cancer (CRC); Sri Lanka; low-middle income country; risk prediction model; validation
Authors: D C Rockey; E Paulson; D Niedzwiecki; W Davis; H B Bosworth; L Sanders; J Yee; J Henderson; P Hatten; S Burdick; A Sanyal; D T Rubin; M Sterling; G Akerkar; M S Bhutani; K Binmoeller; J Garvie; E J Bini; K McQuaid; W L Foster; W M Thompson; A Dachman; R Halvorsen Journal: Lancet Date: 2005 Jan 22-28 Impact factor: 79.321
Authors: Andrew N Freedman; Daniela Seminara; Mitchell H Gail; Patricia Hartge; Graham A Colditz; Rachel Ballard-Barbash; Ruth M Pfeiffer Journal: J Natl Cancer Inst Date: 2005-05-18 Impact factor: 13.506
Authors: G A Colditz; K A Atwood; K Emmons; R R Monson; W C Willett; D Trichopoulos; D J Hunter Journal: Cancer Causes Control Date: 2000-07 Impact factor: 2.506
Authors: Til Stürmer; Julie E Buring; I-Min Lee; J Michael Gaziano; Robert J Glynn Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12 Impact factor: 4.254
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer Journal: CA Cancer J Clin Date: 2008-03-05 Impact factor: 508.702
Authors: Jane A Driver; J Michael Gaziano; Rebecca P Gelber; I-Min Lee; Julie E Buring; Tobias Kurth Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: Don Thiwanka Wijeratne; Sanjeeva Gunasekara; Christopher M Booth; Scott Berry; Matthew Jalink; Laura M Carson; Bishal Gyawali; Hasitha Promod; Umesh Jayarajah; Sanjeewa Seneviratne Journal: JCO Glob Oncol Date: 2022-05